This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.
In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.
View all episodes
By American College of Cardiology
3.8
5454 ratings
This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.
In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.
137 Listeners
320 Listeners
497 Listeners
169 Listeners
885 Listeners
290 Listeners
140 Listeners
1,156 Listeners
41 Listeners
195 Listeners
90 Listeners
364 Listeners
430 Listeners
371 Listeners
32 Listeners